JP2295

JP2295 is a synthetic small molecule analog of diazonamide A, a natural product originally isolated from the marine organism *Diazona angulata*. Developed by Joyant Pharmaceuticals, JP2295 acts as a potent anti-mitotic agent that induces G2/M cell cycle arrest. Its molecular mechanism involves the inhibition of ornithine delta-aminotransferase (OAT), a mitochondrial enzyme that has been identified as a non-canonical target required for proper mitotic spindle assembly. In preclinical rodent models, including pancreatic cancer xenografts, JP2295 demonstrated significant efficacy and a remarkably wider therapeutic window (over 20-fold) compared to traditional anti-mitotic drugs such as taxanes and vinca alkaloids. Its simplified structure, derived from structure-activity relationship (SAR) analyses, allows for more efficient synthesis while maintaining high potency against a broad spectrum of tumors.

Other names

diazonamide analog